Re: Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-Label, Single-Arm, Multicentre, Phase 2 Study

A. V. Balar; A. M. Kamat; G. S. Kulkarni; E. M. Uchio; J. L. Boormans; M. Roumiguié; L. E.M. Krieger; E. A. Singer; D. F. Bajorin; P. Grivas; H. K. Seo; H. Nishiyama; B. R. Konety; H. Li; K. Nam; E. Kapadia; T. Frenkl; R. De Wit

doi:10.1097/JU.0000000000002713

Re: Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-Label, Single-Arm, Multicentre, Phase 2 Study

A. V. Balar, A. M. Kamat, G. S. Kulkarni, E. M. Uchio, J. L. Boormans, M. Roumiguié, L. E.M. Krieger, E. A. Singer, D. F. Bajorin, P. Grivas, H. K. Seo, H. Nishiyama, B. R. Konety, H. Li, K. Nam, E. Kapadia, T. Frenkl, R. De Wit

Cancer Institute of New Jersey (CINJ), Genito Urinary

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	212
Number of pages	1
Journal	Journal of Urology
Volume	208
Issue number	1
DOIs	https://doi.org/10.1097/JU.0000000000002713
State	Published - Jul 1 2022

All Science Journal Classification (ASJC) codes

Urology

Access to Document

10.1097/JU.0000000000002713

Cite this

Balar, A. V., Kamat, A. M., Kulkarni, G. S., Uchio, E. M., Boormans, J. L., Roumiguié, M., Krieger, L. E. M., Singer, E. A., Bajorin, D. F., Grivas, P., Seo, H. K., Nishiyama, H., Konety, B. R., Li, H., Nam, K., Kapadia, E., Frenkl, T., & De Wit, R. (2022). Re: Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-Label, Single-Arm, Multicentre, Phase 2 Study. Journal of Urology, 208(1), 212. https://doi.org/10.1097/JU.0000000000002713

@article{99316ad4889c42159be03ff36b36a78e,

title = "Re: Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-Label, Single-Arm, Multicentre, Phase 2 Study",

author = "Balar, {A. V.} and Kamat, {A. M.} and Kulkarni, {G. S.} and Uchio, {E. M.} and Boormans, {J. L.} and M. Roumigui{\'e} and Krieger, {L. E.M.} and Singer, {E. A.} and Bajorin, {D. F.} and P. Grivas and Seo, {H. K.} and H. Nishiyama and Konety, {B. R.} and H. Li and K. Nam and E. Kapadia and T. Frenkl and {De Wit}, R.",

year = "2022",

month = jul,

day = "1",

doi = "10.1097/JU.0000000000002713",

language = "English (US)",

volume = "208",

pages = "212",

journal = "Journal of Urology",

issn = "0022-5347",

publisher = "Wolters Kluwer Health",

number = "1",

}

Balar, AV, Kamat, AM, Kulkarni, GS, Uchio, EM, Boormans, JL, Roumiguié, M, Krieger, LEM, Singer, EA, Bajorin, DF, Grivas, P, Seo, HK, Nishiyama, H, Konety, BR, Li, H, Nam, K, Kapadia, E, Frenkl, T & De Wit, R 2022, 'Re: Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-Label, Single-Arm, Multicentre, Phase 2 Study', Journal of Urology, vol. 208, no. 1, pp. 212. https://doi.org/10.1097/JU.0000000000002713

Re: Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-Label, Single-Arm, Multicentre, Phase 2 Study. / Balar, A. V.; Kamat, A. M.; Kulkarni, G. S. et al.
In: Journal of Urology, Vol. 208, No. 1, 01.07.2022, p. 212.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Re

T2 - Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-Label, Single-Arm, Multicentre, Phase 2 Study

AU - Balar, A. V.

AU - Kamat, A. M.

AU - Kulkarni, G. S.

AU - Uchio, E. M.

AU - Boormans, J. L.

AU - Roumiguié, M.

AU - Krieger, L. E.M.

AU - Singer, E. A.

AU - Bajorin, D. F.

AU - Grivas, P.

AU - Seo, H. K.

AU - Nishiyama, H.

AU - Konety, B. R.

AU - Li, H.

AU - Nam, K.

AU - Kapadia, E.

AU - Frenkl, T.

AU - De Wit, R.

PY - 2022/7/1

Y1 - 2022/7/1

UR - http://www.scopus.com/inward/record.url?scp=85132974071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85132974071&partnerID=8YFLogxK

U2 - 10.1097/JU.0000000000002713

DO - 10.1097/JU.0000000000002713

M3 - Comment/debate

C2 - 35440150

AN - SCOPUS:85132974071

SN - 0022-5347

VL - 208

SP - 212

JO - Journal of Urology

JF - Journal of Urology

IS - 1

ER -

Re: Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-Label, Single-Arm, Multicentre, Phase 2 Study

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this